Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFINE phase 2 open-label study of navitoclax alone or with ruxolitinib in myelofibrosis
MOH_2021-05-23_009970Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of navitoclax and ruxolitinib in myelofibrosis (MF) (4 cohorts), sponsored by AbbVie Inc. Started May 2021; status: completed.
02
Drugs
navitoclaxruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2021-05-23_009970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-23_009970.